Toxic hepatitis: literature review
Keywords:
Toxic hepatitis, drug hepatitisAbstract
We consider toxic hepatitis to be liver injury caused by chemical or
pharmacological agents and we feel that it should be considered
in the initial differential diagnosis of liver disease. The authors
present a literature review of this subject, including hepatic drug
metabolism physiology, diagnostic criteria, laboratory and clinical presentations, and a review of the classic hepatotoxic drugs,
as well as newer drugs, excipients and “natural” products, that
sometimes cause hepatic damage.
Downloads
References
Almdal TP et al. Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: Analisys of hospitalization registry data. Hepatology 1991;13:650-655.
Ibanez L et al: Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic drugs: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002 ;37(5):592-600.
Biour M et al. Drug-induced hepatotoxicity. The 13th updated edition of the bibliographic database of drug-related liver injuries and responsible drugs. Gastroenterol Clin Biol 2000;24(11):1052-1091.
Labib R et al. Inibition of cocaine oxidative metabolism attenuates endotoxin potentiation of cocaine mediated hepatotoxicity. Toxicology 2002;179(1-2):9-19.
Campos Franco J et al. Cocaine related fulminant liver failure. An Med Interna 2002 ;19(7):365-367.
Nunez O et al. Variability of the clinical expression of ecstasy-induced hepatotoxicity. Gastroenterol Hepatol 2002;25(8):497-500.
Christine A et al: Making a diagnosis of herbal-related toxic hepatitis. West J Med 2002;176(1):39-44.
Larrey D: Drug-induced liver diseases. J Hepatol 2000;32 (1):77-88.
Michael P et al. Immune Aspects of Liver Disease: Lessons for the treatment of autoimmune and viral hepatitis. 8th United European Gasteroenterology Week, November 25 - 30, 2000 – Medscape Conference Coverage http://www.medscape.com/viewarticle/420087
Schenker S et al. Drug disposition and hepatotoxicity in the elderly. J Clin Gastroenterol 1994 ;18(3):232-237.
Bissuel F et al. Fulminant hepatitis with severe lactic acidosis in HIV-infected patients on didanosine therapy. J Intern Med 1994;235:367.
William L: Drug-Induced Hepatotoxicity. N Engl J Med 1995; 333:1118-1127.
Larrey D: Prédisposition Génétique à l´hépatotoxicité des médicaments.Encycl Méd Chir, Hépatologie,7-015-M-44,2002, 5p.
Bacon, Di Bisceglie: Liver Disease Diagnosis and Management – 1st ed. Churchill Livingstone: 294-309
Neil K: Biochemical and Cellular Mechanisms of Toxic Liver Injury. Sem Liver Dis 2002;22(2):137-144
Ramon B et al. Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis. Sem Liver Dis 2001;21(3):437-451.
Liu ZX et al. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002 ;6(3):467-486.
Schenker S et al. Drug disposition and hepatotoxicity in the elderly. J clin Gastroenterol. 1994;18:232.
Fromenty B et al. Inibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995;67(1):101-154.
Berson A et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology
;114(4):764-774.
Farrel GC: Drugs and steatohepatitis. Semin Liver Dis 2002;22(2):185-194.
Schenker S et al. Antecedent liver disease and drug toxicity. J Hepatol 1999;31(6):1098-1105.
Callaghan R et al. Hepatic enzyme activity is the major factor determining elimination rate of high-clearance drugs in cirrhosis. Hepatology
;18(1):54-60.
Ulshen MH et al. Hepatoxicity with encephalopathy associated with aspirin therapy in rheumatoid arthritis. J Pediatr 1978 ;93(6):1034-1037.
Bernstein BH et al. Aspirin-induced hepatotoxicity and its effect on juvenile rheumatoid arthritis. Am J Dis Child 1977 ;131(6):659-663.
Gallo M et al. Acute hepatitis in a patient with adult onset Still disease. Clin Ter 1997;148(4):183-187.
Neuberger J: Halothane hepatitis. Eur J Gastroenterol Hepatol 1998;10(8):631-633.
Hautekeete ML: Hepatotoxicity of antibiotics. Acta Gastroenterol Belg 1995;58(3-4):290-296.
Black M et al. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975;69(2):289-302.
Nolan CM et al. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA
;281(11):1014-1018.
Ansari A et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther
;16(10):1743-1750.
Steen VM et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5(4):215-223.
Olomu AB et al. High incidence of poor sulfoxidation in patients with primary biliary cirrhosis. N Engl J Med 1988 ;318(17):1089-1092.
McFadden SA. Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. Toxicology 1996;111(1-3):43-65.
Spielberg SP et al. Glutathione synthetase-deficient lymphocytes and acetaminophen toxicity. Clin Pharmacol Ther 1981;29(1):51-55.
Leng G et al. Polymorphism of glutathione S-transferases and susceptibility to acrylonitrile and dimethylsulfate in cases of intoxication. Toxicol Lett 2002;134(1-3):209-217.
Norppa H: Cytogenetic markers of susceptibility: influence of polymorphic carcinogen-metabolizing enzymes. Environ Health Perspect 1997;105 (4):829-835.
McNally PR: Drug-Induced Liver Disease. GI/Liver Secrets, Info Access, 1996: 174-175.
Lee WM: Drug-Induced Hepatotoxicity. N Engl J Med 2003; 349:474-485.
Maria VA et al. Lymphocyte reactivity to ex-vivo drug antigens in druginduced hepatitis. J Hepatol 1994;21(2):151-158.
Maria VA et al. Immunological investigation in hepatic drug reactions. Clin Exp Allergy. 1998;28 (4):71-77.
Danan G et al. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46(11):1323-1330.
Danan G et al. Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46(11):1331-1336.
Maria VA et al. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26(3):664-669.
Lucena MI et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001;33(1):123-130.
Sherlock S, Dooley J: Diseases of the Liver and Biliary System – 11th edition. Blackwell Publishing: 335-359.
Neuberger JM: Halothane and hepatitis. Inceidence, predisposing factors and exposure guidelines. Drug Saf 1990 ;5(1):28-38.
Gut J et al. Molecular mimicry in halothane hepatitis: biochemical and structural characterization of lipoylated autoantigens. Toxicology Mar 31;97(1-3):199-224.
Detkova Z et al. Actualités sur les hépatites médicamenteuses. Le Concours Medical Fev 2002 ;124(4) :237-242.
Klein NC et al. Propoxyphene (Darvon) hepatotoxicity. Am J Dig Dis 1971;16(5):467-469.
Desruelles F et al. Hepatotoxicity caused by dextropropoxyphene. Two cases, one of them with recurrence. Therapie 1994;49(6):521-522.
Kanada SA et al. Aspirin hepatotoxicity. Am J Hosp Pharm 1978;35(3):330-336.
Lopez-Morante AJ et al. Aspirin-induced cholestatic hepatitis. J Clin Gastroenterol 1993 ;16(3):270-272.
D’Abrigeon G et al. Liver cirrhosis and granulomatous hepatitis after prolonged ingestion of lysine acetylsalicylate. Gastroenterol Clin Biol
;19(11):944-947.
Trost LC et al. The mitochondrial permeability transition: a new patho-physiological mechanism for Reye’s syndrome and toxic liver injury. J Pharmacol Exp Ther 1996;278(3):1000-1005.
Pessayre D et al. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999;15(6):367-373.
Wood LJ et al. Sulindac hepatotoxicity: effects of acute and chronic exposure. Aust N Z J Med 1985;15(4):397-401.
Jesus E et al. Dois casos de hepatite tóxica pelo diclofenac de sódio. Rev Gastrenterol-Cir 1994;11(53):100-109.
Liu ZX et al. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002 ;6(3):467-486.
Banks AT et al. Diclofenac associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22(3):820-827.
McClain CJ et al. Acetaminophen hepatotoxicity: An update. Curr Gastroenterol Rep 1999;1(1):42-49.
Bessems JG et al: Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol 2001;31(1):55-138.
Rumack BH: Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002;40(1):3-20.
Horowitz S et al. Hepatotoxic reactions associated with carbamazepine therapy. Epilepsia 1988;29(2):149-154.
Schlienger RG et al. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998;39 (7):S3-7.
Ramos AM et al. Reversible vanishing bile duct syndrome induced by carbamazepine. Eur J Gastroenterol Hepatol 2002;14(9):1019-1022.
Gungor E et al. Phenytoin hypersensitivity syndrome. Dig Dis Sci 1993;38(4):740-743.
Lachgar T et al. The drug hypersensitivity syndrome or DRESS syndrome to Phenobarbital. Allerg Immunol (Paris) 2001;33(4):173-175.
Eadie MJ et al. Valproate-associated hepatotoxicity and its biochemical mechanisms. Med Toxicol Adverse Drug Exp 1988 ;3(2):85-106.
Konig SA et al. Fatal liver failure associated with valproate therapy in a patient with Friedreich’s disease: review of valproate hepatotoxicity in adults. Epilepsia 1999;40(7):1036-1040.
Gresser U: Amoxicillin-clavulanic acid therapy may be associated with severe side effects -- review of the literature. Eur J Med Res 2001;6(4):139-149.
Berg P et al. Hepatotoxic reactions induced by beta-lactamase inhibitors. Eur J Med Res 2001;6(12):535-542.
Delgado C et al. Hepatite tóxica medicamentosa. Med-interna 1999;6(2):107-110.
Koek GH et al. Flucloxacillin-associated hepatic injury. Liver 1994;14(5):225-229.
Devereaux BM et al. Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Eur J Clin Pharmacol 1995;49(1-2):81-85.
Maccherini M et al. Ceftriaxone-induced cholelithiasis. Pediatr Med Chir 1998;20(5):341-343.
de Moor RA et al. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr 1999 ;158(12):975-977.
Douglas N et al. Fluoroquinolones Adverse Effects and Drug Interactions. Pharmacotherapy 2001;21(10s):253s-272s.
Contreras MA et al. Severe ciprofloxacin-induced acute hepatitis. Eur J Clin Microbiol Infect Dis 2001;20(6):434-435.
Coleman CI et al. Possible gatifloxacin-induced fulminant hepatic failure. Ann Pharmacother 2002;36(7-8):1162-1167.
Bataille L et al. Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn’s disease. J Hepatol 2002;37(5):696-699.
Derby LE et al. Erythromycin-associated cholestatic hepatitis. Med J Aust 1993;158(9):600-602.
Lienart F et al. Doxycycline and hepatotoxicity. Acta Clin Belg 1992;47(3):205-208.
Bjornsson E et al. Liver reactions to oral low-dose tetracyclines. Scand J Gastroenterol 1997;32(4):390-395.
Bernier C et al. Minocycline. Ann Dermatol Venereol 2001;128(5):627-637.
Berg PA et al. Co-trimoxazole-induced hepatic injury--an analysis of cases with hypersensitivity-like reactions. Infection 1987;15 (5):S259-264.
Junghanss BG: Increase in transaminases in HIV infection. Toxic liver cell damage with trimethoprim/sulfamethoxazole administration in HIV infection. Schweiz Rundsch Med Prax 1998;87(10):361-362.
Paiva LA et al. Long-term hepatic memory for hypersensitivity to nitrofurantoin. Am J Gastroenterol 1992 ;87(7):891-893.
Schattner A et al. Nitrofurantoin-induced immune-mediated lung and liver disease. Am J Med Sci 1999;317(5):336-340.
Amit G et al. Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J 2002;4(3):184-186.
Vasudeva R et al. Isoniazid-related hepatitis. Dig Dis 1997;15(6):357-367.
Nolan CM: Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281(11):1014-1018.
Patel PA: Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002;97(5):1198-1203.
Huang YS et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002;35(4):883-889.
Corbella X et al. Hypersensitivity hepatitis due to pyrazinamide. Scand J Infect Dis 1995;27:93.
Durand F et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995;21(4):929-932.
al Sarraf KA et al. Hepatotoxicity after a short course of low-dose pyrazinamide. Acta Gastroenterol Belg 1996;59(4):251-253.
Jasmer RM et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002;137(8):640-647.
From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. JAMA 2002 ;288(23):2967.
Garcia Rodriguez LA et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999 ;48(6):847-852.
Bradburry BD et al. Itraconazole and Fluconazole and Certain rare, serious adverse events. Pharmacotherapy 2002; 22(6):697-700.
van Outryve S et al. Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review. Neth J Med 2002 ;60(5):216-222.
Stereck M, Wiesner R, Ascher N, Roberts J, Ferrell L, Ludwing J et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991; 14: 806-810.
Bouhnik Y, Lémann M, Mary JY, Scemama G, Taï R, Matuchansky C et al. Long-term follow of patients with Crohn’s disease treated with azathioprine or 6-mercaptupurine. Lancet 1996; 347: 215-259.
Brodsky R et al. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen. Am J Clin Oncol 1990 ;13(3):221-225.
Modzelewski JR et al. Veno-occlusive disease of the liver induced by low-dose cyclophosphamide. Mod Pathol 1994;7(9):967-972.
Herishanu Y et al. The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine. Anticancer Drugs 2002 ;13(2):177-179.
Rush DN: Cyclosporine toxicity to organs other than the kidney. Clin Biochem 1991;24(1):101-105.
Ngo MD et al. Acute hepatitis in the course of cyclosporine therapy of Crohn’s disease. Presse Med 1999 ;28(34):1873-1875.
Hagley MT et al. Hepatotoxicity associated with angiotensin-converting enzyme inhibitors. Ann Pharmacother 1993 ;27(2):228-231.
Webster J et al. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol 1996;27 (3):S49-54.
Thomas LA et al. Acute reactive hepatitis in pregnancy induced by alphamethyldopa. Obstet Gynecol 1997;90(4 Pt 2):658-659.
Bourdi M et al. Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 auto-antibodies. Mol Pharmacol 1994;45(6):1287-1295.
Rigas B et al. The evolving spectrum of amiodarone hepatotoxicity. Hepatology 1989;10(1):116-117.
Breuer HW et al. Amiodarone-induced severe hepatitis mediated by immunological mechanisms. Int J Clin Pharmacol Ther 1998;36(6):350-352.
Jain D et al. Granular cells as a marker of early amiodarone hepatotoxicity. J Clin Gastroenterol 2000;31(3):241-243.
Giannattasio F et al. Three cases of severe acute hepatitis after parenteral administration of amiodarone: the active ingredient is not the only agent responsible for hepatotoxicity. Ann Ital Med Int 2002 ;17(3):180-184.
Punukollu RC et al. Quinine hepatotoxicity. An underrecognized or rare phenomenon? Arch Intern Med 1990 ;150(5):1112-1113.
Hannaford PC et al. Combined oral contraceptives and liver disease. Contraception 1997 ;55(3):145-151.
Farinati F et al. Estrogens receptors and oxidative damage in the liver. Mol Cell Endocrinol 2002 ;193(1-2):85-88.
Presa J et al. Hepatite colestática aguda pela flutamida. Med-interna 2004;11(4):195-196.
Giordano N et al. Acute hepatitis induced by cyproterone acetate. Ann Pharmacother 2001;35(9):1053-1055.
Kacar S et al. Estrogen and cyproterone acetate combination-induced autoimmune hepatitis. J Clin Gastroenterol 2002 ;35(1):98-100.
Stimac D et al. Androgenic/Anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol 2002;35(4):350-352.
Chitturi S et al. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anti-convulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002;22(2):169-183.
Braun JS et al. Hepatitis caused by antidepressive therapy with maprotiline and opipramol. Pharmacopsychiatry 1998 ;31(4):152-155.
Andrade RJ et al. Severe acute hepatitis due to allopurinol in a patient with asymptomatic hyperuricemia and kidney failure. A review of the literature and an analysis of the risk factors. Gastroenterol Hepatol 1997 ;20(7):353-356.
Rabkin JM et al. Liver transplantation for disulfiram-induced hepatic failure. Am J Gastroenterol 1998;93(5):830-831.
Balakirev MY et al. Mitochondrial injury by disulfiram: two different mechanisms of the mitochondrial permeability transition. Chem Biol Interact 2001;138(3):299-311.
Eliasson E et al. Expression of autoantibodies to specific cytochromes P450 in a case of disulfiram hepatitis. J Hepatol 1998;29(5):819-825.
Weiss VC et al. Chronic active hepatitis associated with etretinate therapy. Br J Dermatol 1985 May;112(5):591-597.
Vahlquist A et al. Differential hepatotoxicity of two oral retinoids (etretinate and isotretinoin) in a patient with palmoplantar psoriasis. Acta Derm Venereol 1985;65(4):359-362.
Fallon MB et al. Hepatic toxicity of vitamin A and synthetic retinoids. J Gastroenterol Hepatol 1990;5(3):334-342.
Torres M et al. Acute cholestatic hepatitis induced by cerivastatin. Med Clin (Barc) 2002;118(18):717.
Bolego C et al. Safety considerations for statins. Curr Opin Lipidol 2002;13(6):637-644.
Ganne-Carrie N et al. Autoimmune hepatitis induced by fibrates. Gastroenterol Clin Biol 1998;22(5):525-529.
Guimarães F et al. Hepatotoxicidade por ticlopidina: a propósito de três casos clínicos. Med-interna 2001;8(2):132-137.
Remy AJ et al. Acute hepatitis after riluzole administration. J Hepatol 1999;30(3):527-530.
Assal F et al. Tolcapone and fulminant hepatitis. Lancet 1998;352(9132):958.
Haasio K et al. Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo. Exp Toxicol Pathol 2002;54(1):9-14.
Odeh M et al. Severe hepatotoxicity with jaundice associated with paroxetine. Am J Gastroenterol 2001;96(8):2494-2496.
Azaz-Livshits T et al. Paroxetine associated hepatotoxicity: a report of 3 cases and a review of the literature. Pharmacopsychiatry 2002 ;35(3):112-115.
Fartoux-Heymann L et al. Acute fatal hepatitis related to sertraline. J Hepatol 2001;35(5):683-684.
Carvajal GP et al. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 2002 ;63(2):135-137.
Carr A et al. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-1430.
Dusoleil A et al. Glimepiride-induced acute hepatitis. Gastroenterol Clin Biol 1999;23(10):1096-1097.
Sitruk V et al. Acute cholestatic hepatitis induced by glimepiride. Gastroenterol Clin Biol. 2000;24(12):1233-1234.
Diaz-Gutierrez FL et al. Acarbose-induced acute hepatitis. Am J Gastroenterol 1998;93(3):481.
Carrascosa M et al. Acarbose-induced acute severe hepatotoxicity. Lancet 1997;349(9053):698-699.
Watkins PB et al. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998;338(13):916-917.
Li H et al. Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings. J Diabetes Complications 2000;14(3):175-177.
May L et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002;136:449-452.
Bonkovsky HL et al. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci 2002 ;47(7):1632-1637.
Gouda HE et al. Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med. 2001 ;111(7):584-585.
Dhawan M et al. Rosiglitazone-induced granulomatous hepatitis. J Clin Gastroenterol 2002 ;34(5):582-584.
Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 2001;24(12):873-888.
Ferreiro C et al. Hepatitis tóxica por nimesulida. Presentación de un nuevo caso y revisión de la bibliografía. Gastroenterol Hepatol 2000;23(9):428-430.
Merlani G et al. Fatal hepatoxicity secondary to nimesulide. Eur J Clin Pharmacol 2001;57(4):321-326.
Dumortier J et al. Subfulminant hepatitis associated with nimesulide treatment requiring liver transplantation. Gastroenterol Clin Biol 2002;26(4):415-416.
Boelsterli UA et al. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf 2002;25(9):633-648.
Rodrigo L et al. Nimesulide-induced severe hemolytic anemia and acute liver failure leading to liver transplantation. Drug Saf 2002;25(9):633-648.
Galan MV et al. Celecoxib-induced cholestatic hepatitis. Ann Intern Med 2001;134(3):254.
Grieco A et al. Acute cholestatic hepatitis associated with celecoxib. Ann Pharmacother 2002 ;36(12):1887-1889.
Huster D et al. Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS). J Hepatol 2002 ;37(3):413-414.
Reinus JF et al. Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast. Ann Intern Med 2000 ;133(12):964-968.
Actis GC et al. Zafirlukast-related hepatitis: report of a further case. J Hepatol 2001;35(4):539-541.
Danese S et al. Severe liver injury associated with zafirlukast. Ann Intern Med 2001;135(10):930.
Suriaqinata A et al. A 33-year-old woman with jaundice after azithromicin use. Semin Liver Dis 2002;22(2):207-210.
Chandrupatla S et al. Azithromicin induced intrahepatic cholestasis. Dig Dis Sci 2002;47(10):2186-2188.
Gomez Caturla A et al. Acute hepatitis associated with lamotrigine administration. Med Clin (Barc) 1998;111(17):675-676.
Overstreet K et al. Fatal progressive hepatic necrosis associated with lamotrigine treatment: a case report and literature review. Dig Dis Sci 2002;47(9):1921-1925.
Veyrac G et al. Characteristics of hypersensitivity syndrome to lamotrigine: review of one case reported in the Regional Center of Pharmacovigilance of Nantes. Therapie 2002 ;57(3):289-296.
Willens HJ. Clopidogrel-induced mixed hepatocellular and cholestatic liver injury. Med Clin (Barc) 2002 ;119(1):37.
Duran Quintana JA et al. Clopidogrel probably induced hepatic toxicity. Med Clin (Barc) 2002;119(1):37.
Oien KA et al. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999 ;353(9146):36-37
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
